Kaken Pharmaceutical — Patent Portfolio
1 drug with active patents · 20 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Verdict Kaken Pharmaceutical's portfolio is moderately strong, with a significant cliff year in 2026 and no revenue at risk in the next 5 years.
Portfolio overview Kaken Pharmaceutical has a total of 20 US patents, with all 20 being active. The average vulnerability score of these patents is 68, indicating a moderate level of vulnerability. The company has 2 ironclad patents and 17 vulnerable patents. Notably, the company has no biologics in its portfolio.
Cliff calendar In 2026, 1 drug will lose exclusivity, including Ecclock. This marks a significant cliff year for the company. Additionally, the company's portfolio will experience a steady decline in exclusivity over the next few years.
Most exposed drugs The top drug facing near-term loss of exclusivity is Ecclock, with an earliest active patent expiry date of 2026-11-13 and an average vulnerability score of 68. Ecclock is a brand name for the generic drug Sofpironium Bromide. Unfortunately, the annual revenue for Ecclock is not available.
Biologic exclusivity Kaken Pharmaceutical has no biologics in its portfolio, meaning it does not have any biologics with BPCIA 12-year reference product exclusivity.
Strategic implications The company has no revenue at risk in the next 5 years. However, the loss of exclusivity for Ecclock in 2026 will require the company to consider lifecycle moves to maintain revenue. This may include subQ switches, label extensions, or combination filings.
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Ecclock (SOFPIRONIUM BROMIDE)
Cliff 2026 · 0y-
US8628759
Vuln 93
2026-11-13
This patent protects a class of compounds known as soft anticholinergic esters with specific chemical formulas.
-
US9492429
Vuln 75
2034-03-14
This patent protects a method of treating hyperhidrosis by topically administering a composition containing a specific compound to the skin before bedtime.
-
US9895350
Vuln 75
2034-03-14
This patent protects a method of treating hyperhidrosis in mammals by topically administering a composition containing a specific compound to the skin before bedtime.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Method of Use 17 patents
- Composition of Matter 3 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track Kaken Pharmaceutical's patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export